12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.

Phase 2 Completed 625 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to measure the safety and efficacy of four dosing strategies of CP-526,555 for 12 weeks compared with placebo for smoking cessation. Post-treatment follow-up of smoking status to one year from randomization was performed in a non-treatment extension Protocol A3051018

Timeline

Start: 2001-09
Primary completion: —
Completion: 2002-10

Publications

Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	0.5 mg	—
Subject	Varenicline	Small molecule	1 mg	—

Indications

No indication recorded.